CORE--STEM CELLS

$202,050P01FY2000HLNIH

St. Jude Children'S Research Hospital, Memphis TN

Investigators

Linked publications & trials

Paper 39086133 Paper 38359264 Paper 37400614 Paper 37069266 Paper 36996170 Paper 36907613 Paper 36907603 Paper 36592307 Paper 36522432 Paper 36413407 Paper 36224385 Paper 35934593 Paper 35830837 Paper 35793591 Paper 35618846 Paper 35526095 Paper 34628053 Paper 34341563 Paper 33958780 Paper 33956057 Paper 33855970 Paper 33846636 Paper 33054091 Paper 32995355 Paper 32983414 Paper 32949809 Paper 32897878 Paper 32541958 Paper 32433547 Paper 32341484 Paper 32284612 Paper 32154328 Paper 32054658 Paper 31890741 Paper 31636237 Paper 30995372 Paper 30911135 Paper 28190779 Paper 27099176 Paper 26761813 Paper 26665131 Paper 26052531 Paper 26015964 Paper 25681747 Paper 25545666 Paper 25082879 Paper 24711620 Paper 24687960 Paper 24487563 Paper 24139498 Paper 24079872 Paper 23843498 Paper 23786330 Paper 23626802 Paper 23297344 Paper 22871664 Paper 22842333 Paper 22434139 Paper 22130804 Paper 22102623 Paper 21321359 Paper 21156846 Paper 20495075 Paper 20457870 Paper 20393131 Paper 20372106 Paper 20190190 Paper 19521564 Paper 19509470 Paper 19365082 Paper 19286997 Paper 19234465 Paper 19223867 Paper 19179303 Paper 19050697 Paper 18283610 Paper 18195719 Paper 17991809 Paper 17601756 Paper 17043654 Paper 17024180 Paper 16864781 Paper 16831572 Paper 16763211 Paper 16648487 Paper 16263792 Paper 16024775 Paper 15956585 Paper 15950458 Paper 15831758 Paper 15781335 Paper 15703496 Paper 15692066 Paper 15508113 Paper 15273251 Paper 15226440 Paper 15198957 Paper 15084587 Paper 14993294 Paper 14976042

Abstract

The purpose of this core is to prepare human CD34+ and CD34+, CD38- and other primitive hematopoietic cell populations for use in projects which have a requirement for such cells. This Core has access to Good Manufacturing Practice (GMP) facilities, including a cell sorter facility, in which donor harvests for autologous and allogeneic transplants are processed, providing a potential source of cells for experimental use. In addition, samples will be obtained from normal volunteers and patient- volunteers with sickle cell disease. Primitive hematopoietic cell populations will be prepared from bone marrow, peripheral blood and cord blood, to meet the varying requirements for each project.

View original record on NIH RePORTER →